RT Generic
T1 Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review
A1 De Diego-Adelino, Javier
A1 Crespo, Jose Manuel
A1 Mora, Fernando
A1 Neyra, Adrian
A1 Iborra, Pedro
A1 Gutierrez-Rojas, Luis
A1 Salonia, Selman F.
K1 Antidepressant
K1 cognition
K1 efficacy
K1 interactions
K1 major depressive disorder
K1 neurotransmission
K1 pharmacology
K1 safety
K1 vortioxetine
K1 Serotonin reuptake inhibitors
K1 Multimodal antidepressant vortioxetine
K1 Randomized controlled-trials
K1 Emergent sexual dysfunction
K1 Placebo-controlled trials
K1 Substance use disorders
K1 Inadequate response
K1 Double-blind
K1 5-ht3 receptors
K1 Open-label
AB Introduction Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options for major depressive disorder (MDD) in head-to-head trials. Areas covered The present review intends to gather the most relevant and pragmatic data of vortioxetine in MDD, specially focusing on new studies that emerged between 2015 and 2020. Expert opinion Vortioxetine is the first antidepressant that has shown improvements both in depression and cognitive symptoms, due to the unique multimodal mechanism of action that combine the 5-HT reuptake inhibition with modulations of other key pre- and post-synaptic 5-HT receptors (agonism of 5-HT1A receptor, partial agonism of 5-HT1B receptor, and antagonism of 5-HT3, 5-HT1D and 5-HT7 receptors). This new mechanism of action can explain the dose-dependent effect and can be responsible for its effects on cognitive functioning and improved tolerability profile. Potential analgesic and anti-inflammatory properties observed in preclinical studies as well as interesting efficacy and tolerability results of clinical studies with specific target groups render it a promising therapeutic option for patients with MDD and concomitant conditions (as menopause symptoms, pain, inflammation, apathy, sleep and/or metabolic abnormalities).
PB Taylor & francis ltd
SN 1474-0338
YR 2021
FD 2021-12-29
LK https://hdl.handle.net/10668/26044
UL https://hdl.handle.net/10668/26044
LA en
DS RISalud
RD Apr 10, 2025